RMTG — Regenerative Medical Technology Balance Sheet
0.000.00%
- $0.45m
- $18.43m
- $5.10m
Annual balance sheet for Regenerative Medical Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.98 | 1.65 | 0.531 | 1.17 | 0.957 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.017 | 0.05 | 0.024 | 0.023 | 0.044 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.02 | 1.69 | 0.575 | 1.25 | 1.22 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.023 | 0.22 | 0.362 | 0.727 | 1.49 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 9.31 | 8.08 | 2.88 | 3.82 | 4.49 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.22 | 12 | 22.2 | 29 | 36.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 16.1 | 20.1 | 24.7 | 31.2 | 39.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -6.76 | -12 | -21.8 | -27.4 | -34.7 |
| Total Liabilities & Shareholders' Equity | 9.31 | 8.08 | 2.88 | 3.82 | 4.49 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |